Recent Updates
Recently added Catalysts
LQDA Positive Sentiment

Liquidia Corporation Reports Second Quarter 2026 Financial Results

Wednesday, August 12, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Liquidia Corporation reported strong financial results for the second quarter of 2026, with net product sales of YUTREPIA® (treprostinil) inhalation powder reaching approximately $170.4 million. This marks a 31% increase from the first quarter of 2026. The company noted that around 5,900 unique patient prescriptions were filled, with more than 5,000 patients treated since the product's launch in June 2025.

Market Sentiment Analysis

POSITIVE FACTORS

  • Net product sales increased by 31% from the previous quarter.
  • Approximately 5,900 unique patient prescriptions were recorded.
  • Over 5,000 patients have been treated since the product launch.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+71%
120-day peak, hindsight
Typical move
5%
average across 2 past catalysts
Lead asset
L606
Phase 3 · Pulmonary Arterial Hypertension

Full Press Release Details

YUTREPIA ® (treprostinil) inhalation powder net product sales of approximately $170.4 million in the second quarter of 2026, up 31% from the first quarter of 2026 Approximately 5,900 unique patient prescriptions and more than 5,000 patients treated between launch in June 2025 and July 31, 2026

Frequently Asked Questions

What were Liquidia's net product sales in Q2 2026?

Liquidia's net product sales for Q2 2026 were approximately $170.4 million.

How much did sales increase from Q1 to Q2 2026?

Sales increased by 31% from the first quarter to the second quarter of 2026.

How many patients were treated with YUTREPIA®?

More than 5,000 patients have been treated with YUTREPIA® since its launch.

When was YUTREPIA® launched?

YUTREPIA® was launched in June 2025.

ShareAdd on Google
Tags: LQDA Viatris Investor Conferences Healthcare Liquidia Corporation YUTREPIA treprostinil financial results Q2 2026
Last updated: Aug 12, 2026

Biotech snapshot

Cash runway
$284M liquidity · $0M/mo burn
Low dilution risk
Lead asset
L606Phase 3
Pulmonary Arterial Hypertension →

Catalyst track record

+71%
best trade around LQDA's most recent catalyst

Peak hindsight return over a 120-day window, across 2 tracked FDA/PDUFA catalysts for LQDA.

See every catalyst's timing & PoA →